StockData
Pulmonx Corp logo

Pulmonx Corp (LUNG) stock

LUNGNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 7/3044% below fair value
$2.69−0.04 (-1.65%)

Close on Nov 18, 2026Market cap $115.53MP/E –Yield –

Pulmonx operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Pulmonx's operating income for the twelve months ending Jun 30, 2026 was -$46.31M. For fiscal 2025 it was -$53.66M. The highest annual figure on record is -$15.05M in fiscal 2018.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$53.66M–
FY2024Dec 31, 2024-$57.70M–
FY2023Dec 31, 2023-$61.94M–
FY2022Dec 31, 2022-$58.64M–
FY2021Dec 31, 2021-$47.30M–
FY2020Dec 31, 2020-$32.33M–
FY2019Dec 31, 2019-$17.84M–
FY2018Dec 31, 2018-$15.05M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$9.06M–
Q1 FY2026Mar 31, 2026-$12.96M–
Q4 FY2025Dec 31, 2025-$9.90M–
Q3 FY2025Sep 30, 2025-$14.39M–
Q2 FY2025Jun 30, 2025-$14.80M–
Q1 FY2025Mar 31, 2025-$14.56M–
Q4 FY2024Dec 31, 2024-$13.42M–
Q3 FY2024Sep 30, 2024-$14.13M–
Q2 FY2024Jun 30, 2024-$15.62M–
Q1 FY2024Mar 31, 2024-$14.54M–
Q4 FY2023Dec 31, 2023-$13.92M–
Q3 FY2023Sep 30, 2023-$15.18M–
Q2 FY2023Jun 30, 2023-$16.44M–
Q1 FY2023Mar 31, 2023-$16.40M–
Q4 FY2022Dec 31, 2022-$14.63M–
Q3 FY2022Sep 30, 2022-$13.93M–
Q2 FY2022Jun 30, 2022-$14.41M–
Q1 FY2022Mar 31, 2022-$15.67M–
Q4 FY2021Dec 31, 2021-$12.37M–
Q3 FY2021Sep 30, 2021-$9.76M–
Q2 FY2021Jun 30, 2021-$12.68M–
Q1 FY2021Mar 31, 2021-$12.49M–
Q4 FY2020Dec 31, 2020-$9.35M–
Q3 FY2020Sep 30, 2020-$5.35M–
Q2 FY2020Jun 30, 2020-$11.53M–
Q1 FY2020Mar 31, 2020-$6.10M–
Q4 FY2019Dec 31, 2019-$4.29M–
Q3 FY2019Sep 30, 2019-$3.61M–

More Pulmonx figures

See a number that looks wrong?